Navigation Links
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

Believed by experts to be important for cervical cancer prevention

GRAZ, Austria, May 14 /PRNewswire-FirstCall/ -- New data from an extended follow-up study show that GlaxoSmithKline (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX(R) generates sustained high levels of neutralizing antibodies against the two most common cervical cancer-causing human papillomavirus types for up to 6.4 years. This is the longest duration of sustained neutralizing antibody levels observed against both virus types 16 and 18 with a cervical cancer vaccine to date.

Experts believe that neutralizing antibodies -- so-called because they have the ability to neutralize cancer-causing virus types and prevent them from infecting cells in the cervix -- are essential for cervical cancer protection. The World Health Organization has stated that neutralizing antibodies are "considered to be the major basis" of vaccine-induced protection from infection.

In addition, the study found that the level of total antibodies induced by the candidate vaccine was sustained and 11 times higher than the total antibody levels induced after natural infection for up to 6.4 years. This new data confirms previous findings from the vaccine's studies showing that, when total antibody levels are high, neutralizing antibody levels are also elevated.

"We designed our cervical cancer vaccine with our proprietary Adjuvant System, AS04, to deliver high and sustained levels of neutralizing antibodies to prevent cervical cancer over the long-term," said Philippe Monteyne, Senior Vice President, GSK Biologicals. "With nearly six and a half years of data, the vaccine has already been shown to provide the longest duration of protection of any cervical cancer vaccine to date. The high and sustained neutralizing antibody levels we observe over this same period give us confidence that the vaccine will continue to protect for even longer. This is why we are extending the study follow-up in a sub-set of women for up to 9.5 years, the longest follow-up period for any cervical cancer vaccine."

This trial included more than 700 women aged 15-25 years. During the same period that the candidate vaccine induced sustained high antibody levels for both virus types 16 and 18, the vaccine had been shown to provide 100 percent efficacy against those cancer-causing virus types.

These data were presented today at the European Society for Paediatric Infectious Diseases (ESPID) annual meeting in Graz, Austria.

Notes to the editors:

-- Safety data from 11 trials involving almost 30,000 women ages 10-72

years who received either the candidate vaccine or a control were also

presented at ESPID. During the course of vaccination and after the

completion of the three-dose schedule no differences were observed

between the candidate vaccine and control groups in serious adverse

events, medically significant conditions and new onset of autoimmune


-- Compliance with the three-dose schedule was excellent in the 11 trials

of the integrated safety summary.

About the study

This was an extended follow-up (EFU) analysis of women who participated in the initial efficacy study of GSK's cervical cancer candidate vaccine. The initial study was a double-blind, controlled trial of 1,113 young women between 15-25 years of age, randomized to receive three doses of the candidate vaccine, formulated with the AS04 adjuvant system, or three doses of placebo on a 0, 1 and 6 month schedule.

This extended follow-up study looked at study endpoints for 776 women from the same cohort of women for a period of up to 6.4 years post-vaccination. The trial was conducted in 28 centers in Brazil, Canada and the U.S. and evaluated the efficacy, safety and immunogenicity of GSK's candidate vaccine for the prevention of infection with cancer causing virus types 16 and/or 18, and other cancer-causing virus types, as well as prevention of associated Pap smear abnormalities and cervical precancerous lesions. In the extended follow-up study, women were evaluated for the presence of human papillomavirus DNA by PCR using cervical samples and annual cervical cytology evaluations were performed. Women were referred for colposcopy following protocol guidelines. Women were also assessed for long-term immunogenicity and safety.

About cervical cancer and its progression

Approximately 100 types of human papillomavirus have been identified to date and, of these, approximately 15 virus types are known to cause cervical cancer. Virus types 16, 18, 45 and 31 are responsible for approximately 80 percent of cervical cancers globally. Persistent infection with cancer-causing virus types can lead to the formation of abnormal cells in the cervix, which, over time, may become precancerous or cancerous. Human papillomavirus is a necessary precursor of cervical cancer. Throughout their lifetime, women may be exposed to cancer-causing virus types and are potentially at risk of developing cervical cancer.

Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer and over 280,000 women will die from it each year.

About the GSK Cervical Cancer Vaccine

To date, CERVARIX(R) has been approved in more than 60 countries around the world including the 27 member countries of the European Union, Mexico, Australia, Singapore and the Philippines. Licensing applications have been submitted in more than 35 additional countries including Japan. GSK also submitted CERVARIX(R) to the World Health Organization (WHO) for prequalification in September 2007.

GSK submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its cervical cancer vaccine in March 2007.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world -- an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children with up to six diseases in one vaccine.

CERVARIX(R) is a registered trademark of the GlaxoSmithKline group of companies.


(1) Wheeler C, Teixeira J, et al. High and sustained HPV-16 and 18

antibody levels through 6.4 years in women vaccinated with CERVARIX

(GSKS HPV 16/18 AS04 vaccine) To be presented at: ESPID May 14, 2008

(2) Clifford GM, Smith JS, et al. Human papillomavirus types in invasive

cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88: 63-


(3) GSK Data on File

(4) Villa L. Vaccines against papillomavirus infections and disease.

Revista Chilena de Infectologia. 2006; 23(2): 160-163

(5) The World Health Organization. Human papillomavirus and HPV vaccines:

technical information for policy-makers and health professionals.

Available at:


(6) Schuind A. HPV-007 Final Analysis. Presented at: SGO's Annual Meeting

on Women's Cancer. March 10, 2008

(7) Dessy F, David MP, Schuind A et al. Evaluation of HPV neutralizing

antibodies from an extended follow up study through 5.5 years in women

vaccinated with GSKs prophylactic Cervical Cancer Candidate Vaccine.

Presented at IPC 2007

(8) Deschamps D, Hardt K, Spiessens B et al. Safety of human

papillomavirus (Hpv)-16/18 AS04 adjuvanted vaccine for cervical cancer

prevention: integrated summary of 11 clinical trials. Presented at

ESPID 2008

(9) Harper DM, Franco EL, Wheeler C, Ferris DG, et al. Efficacy of a

bivalent L1 virus-like particle vaccine in prevention of infection

with human papillomavirus types 16 and 18 in young women: a randomised

controlled trial. Lancet 2004;364:1757-65.

(10) Harper DM, Franco EL et al. Sustained efficacy up to 4.5 years of a

bivalent L1 virus-like particle vaccine against human papillomavirus

types 16 and 18: follow-up from randomised control trial. The Lancet

2006; 367: 1247-1255.

(11) Gall, S., et al. Sustained Efficacy up to 5.5 years in women

vaccinated with an AS04 Adjuvanted HPV 16/18 L1 VLP Vaccine. Presented

at AACR Medical Meeting. April 17, 2007.

(12) Harper DM, Gall S, et al. HPV-007 Efficacy Abstract. "Sustained

Immunogenicity and high efficacy against HPV-16/18 related cervical

neoplasia: Long-term follow-up through 6.4 years in women vaccinated

with CERVARIX (GSKS HPV 16/18 AS04 Candidate vaccine)" Presented at:

SGO's Annual Meeting on Women's Cancer. March 10, 2008 Tampa

Convention Center.

(13) Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic

cervical human papillomavirus infection. Infect Dis Clin North Am,

2005; 19:439-458

(14) Munoz N, Bosch FX, de Sanjose S,et al. Epidemiologic classification

of human papillomavirus types associated with cervical cancer. N Engl

J Med 2003; 348: 518-527

(15) Munoz N, Bosch FX, Castellsague X et al. Against which human

papillomavirus types shall we vaccinate and screen? The international

perspective. Int. J. Cancer 2004; 111; 278-285

(16) Baseman JG, Koutsky LA. The epidemiology of human papillomavirus

infections J Clin Virol 2005; 32 Suppl 1; S16-24

(17) World Health Organization. Initiative for Vaccine Research. Accessed on May

2, 2007

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
3. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
4. Evotecs EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
9. Raptor Pharmaceuticals Provides Update of Product Programs
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
(Date:11/24/2015)... 24, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Executive Officer Doug Godshall is scheduled to ... Healthcare Conference on December 1, 2015 at 3:00 p.m. ... New York . ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... 2015 F1000Workspace - a research ... it was launched just six months ago. --> ... platform for scientists - since it was launched just six ... loaded on to F1000Workspace - a research collaboration, ... was launched just six months ago. --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving ... dropped below 10,000 for the first time since 2011. In 2014, there were 9,967 ... data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent breast reconstruction ... incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my ... RECOVERY BRA for added comfort and support. The bra is easier to put ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
Breaking Medicine News(10 mins):